Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes

Patients’ selection is particularly important in cancer treatment. Here the authors present a proof-of-principle methodology that could be potentially important in assisting therapeutic decisions in the treatment of breast cancer patients.

Guardado en:
Detalles Bibliográficos
Autores principales: Valeriy Domenyuk, Zoran Gatalica, Radhika Santhanam, Xixi Wei, Adam Stark, Patrick Kennedy, Brandon Toussaint, Symon Levenberg, Jie Wang, Nianqing Xiao, Richard Greil, Gabriel Rinnerthaler, Simon P. Gampenrieder, Amy B. Heimberger, Donald A. Berry, Anna Barker, John Quackenbush, John L. Marshall, George Poste, Jeffrey L. Vacirca, Gregory A. Vidal, Lee S. Schwartzberg, David D. Halbert, Andreas Voss, Daniel Magee, Mark R. Miglarese, Michael Famulok, Günter Mayer, David Spetzler
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/5a4c54b8e9744dccbcb331d197302fe8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/5a4c54b8e9744dccbcb331d197302fe8

Ejemplares similares